NUVB

Nuvation Bio (NUVB) is the lead sponsor of 6 active clinical trials listed on ClinicalTrials.gov^[4], including 3 Phase 3^[1], 3 Phase 2^[2], 1 Phase 1^[3].

Trial NCT05303519^[5] evaluates safusidenib in Glioma with a target enrollment of 365 participants. Trial NCT07154706^[6] evaluates Taletrectinib in Non-small Cell Lung Cancer (NSCLC) with a target enrollment of 180 participants. Trial NCT06564324^[7] evaluates Taletrectinib in Non Small Cell Lung Cancer with a target enrollment of 138 participants.

NUVB has 1 Form 4 insider filing recorded at the SEC in the past 30 days^[8].